ClinicalTrials.gg
TerminatedNCT04752371Updated Aug 23, 2023

A Study to Evaluate Camoteskimab in Participants With Still's Disease

A Phase 1 interventional study of Camoteskimab (CERC-007, AVTX-007, AEVI-007) in Adult Onset Still's Disease, sponsored by Apollo Therapeutics Ltd. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Apollo Therapeutics Ltd · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor discretion

From the registry’s dates

  • Primary completion was May 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.

02

Conditions studied

  • Adult Onset Still's Disease

Keywords

  • Adult Onset Still's Disease
  • AEVI-007
  • Camoteskimab
  • IL-18
  • sJIA
03

In context

Still's Disease, Adult-Onset

23 studies on the registry are indexed under Still's Disease, Adult-Onset; 5 are open to participants now.

This study's enrollment of 5 is below the median of 14 across 11 interventional studies indexed under Still's Disease, Adult-Onset.

Browse Still's Disease, Adult-Onset studies →

Lead sponsor

Apollo Therapeutics Ltd is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 to 75 years of age (inclusive) at the time of consent. The date of signature of the is defined as the beginning of the Screening Period. This inclusion criterion will only be assessed at the Screening Visit (Visit 1).
  2. Subject has been diagnosed with AOSD based on classification criteria (according to Yamaguchi et al, 1992) defined as having 5 or more of the following criteria, 2 of which are major:

    a. Major Criteria i. Fever >39°C, lasting 1 week or longer ii. Arthralgia or arthritis, lasting 2 weeks or longer iii. Typical rash iv. Leukocytes >10,000 mm3 with >80% polymorphonuclear cells b. Minor Criteria i. Sore throat ii. Recent development of significant lymphadenopathy iii. Hepatomegaly or splenomegaly iv. Abnormal liver function tests v. Negative tests for antinuclear antibody and rheumatoid factor

  3. Subject has reported a recurring fever >38°C, consistent with active disease, within the last 5 days of the Screening and Baseline Visits.
  4. If undergoing treatment with non-steroidal anti-inflammatory drugs (NSAID), subject is on a stable dose for at least 48 hours prior to the Baseline Visit (Visit 2).
  5. If undergoing treatment with , subject is on a stable dose for at least 48 hours prior to the Baseline Visit (Visit 2).
  6. If undergoing treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs), subject is on a stable dose for at least 4 weeks prior to the Baseline Visit (Visit 2).
  7. For subjects who have received treatment with biological DMARDs, subject has the required (normalization) period prior to the Baseline Visit (Visit 2).

    The washout (normalization) period for biological DMARDs is as follows:

    1. Anakinra - 1 week
    2. Etanercept, rilonacept - 4 weeks
    3. Adalimumab, certolizumab, infliximab, golimumab, abatacept, tocilizumab and canakinumab - 8 weeks
    4. Rituximab - 36 weeks
  8. Non-pregnant female subjects of who are heterosexually active and non-sterile male subjects with female sexual partners of childbearing potential agree to use a highly effective method of during treatment and for 25 weeks following the last dose of product. A highly effective method of birth control is defined as one that results in a low failure rate (ie, \<1% per year) when used consistently and correctly, such as oral/injectable/inserted/implanted/transdermal contraceptives, intrauterine hormone-releasing system or intrauterine device (IUD), or sexual abstinence. Contraception is not required where at least 6 weeks has passed since sterilization, defined as females having undergone one of the following surgeries: hysterectomy, bilateral tubal ligation or occlusion, bilateral oophorectomy, or bilateral salpingectomy; and males who are vasectomized. Contraception is also not required where females are (defined as 12 consecutive months of spontaneous amenorrhea and age ≥51 years). Females of must have a negative pregnancy test as part of the screening/baseline assessment.
  9. Subject has provided written informed consent for this study.
  10. Subject is willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject is, in the opinion of the investigator, mentally or legally incapacitated, or has significant emotional problems at the time of the Screening Visit (Visit 1) that could interfere with the subject's participation or cooperation with the conduct of study evaluations
  2. Subject has a chronic severe or uncontrolled medical disorder that might confound the results of safety assessments conducted in the study in the opinion of the Investigator or Medical Monitor.
  3. Subject has another serious chronic-inflammatory disease.
  4. Subject has a relevant, active infection or another disease, which entails a tendency towards infection.
  5. Subject has active macrophage activation syndrome.
  6. Subject has a history of unresolved latent tuberculosis.
  7. Subject has the following abnormal values:

    1. Serum creatinine concentration >1.5 mg/dl.
    2. ≤ 10 g/dl, neutrophils ≤1,500/μl and/or ≤75,000/μl.
  8. Subject has a history of neoplasia with the exception of a curatively treated non-melanoma skin tumor or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years.
  9. Subject has received a vaccination with a within 12 weeks prior to the Baseline Visit (Visit 2).
  10. Subject has used an product or been enrolled in a clinical study including vaccines within 30 days of the Screening Visit (Visit 1).
  11. Subject has known or suspected intolerance or to the investigational product(s), closely related compounds, or any ingredients of the investigational product.
  12. Subject is pregnant or is breastfeeding and will not abstain from breastfeeding during participation in the study and for 25 weeks post last dose of investigational product.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Cohort 1: Camoteskimab 7 mg/kg

    6 participants will be administered camoteskimab at a dose of 7 mg/kg (500 mg maximum) at Baseline, Week 4, and Week 8.

    Drug: Camoteskimab (CERC-007, AVTX-007, AEVI-007)

  • Experimental
    Cohort 2: Camoteskimab Dose escalation/reduction

    Cohort 2 dose will be determined based on a review of Cohort 1 data. 6 participants will be administered camoteskimab at the determined dose at Baseline, Week 4, and Week 8.

    Drug: Camoteskimab (CERC-007, AVTX-007, AEVI-007)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of AEs

    Time frame: Baseline to Week 24

  2. Incidence of Clinically Significant Changes from Baseline in Vital Signs

    Time frame: Baseline to Week 24

  3. Incidence of Clinically Significant Changes from Baseline in Clinical Laboratory Results

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of subjects who achieved absence of fever

    Fever defined as no temperature \> 38 degrees Celcius for 48 hours

    Time frame: Baseline to Week 24

  2. Proportion of subjects whose C-Reactive Protein (CRP) Levels Reduced by 50% or more from Baseline

    Time frame: Baseline to Week 4 and Week 12

  3. Change from Baseline in the Physician Global Assessment of Disease Activity

    Physician global assessment of disease activity will be assessed using a Visual Analogue Scale (VAS) where 0 mm indicates no evidence of disease and 100 mm indicates very severe disease activity.

    Time frame: Baseline to Week 4 and Week 12

  4. Change from Baseline in the Patient Global Assessment of Disease Activity

    Patient global assessment of disease activity will be assessed using a Visual Analogue Scale (VAS) where 0 mm indicates no evidence of disease and 100 mm indicates very severe disease activity.

    Time frame: Baseline to Week 4 and Week 12

  5. Change from Baseline in the modified Pouchot score

    Time frame: Baseline to Week 4 and Week 12

  6. Change from Baseline in the Disease Activity Score-28 with C-Reactive Protein (DAS28-CRP)

    Time frame: Baseline to Week 4 and Week 12

  7. Change from Baseline in CRP, ferritin, and ESR

    Time frame: Baseline to Week 4 and Week 12

  8. Serum Concentration of camoteskimab

    Time frame: Baseline through Week 24

07

Study locations

11 sites
  • Sponsor Investigative Site
    Gainesville, Florida 32610, United States
  • Sponsor Investigative Site
    Ann Arbor, Michigan 48109, United States
  • Sponsor Investigative Site
    Gent, Oost-Vlaanderen 9000, Belgium
  • Sponsor Investigative Site
    Elbląg, 82-300, Poland
  • Sponsor Investigative Site
    Pomorskie, 85-168, Poland
  • Sponsor Investigative Site
    Poznań, 61-113, Poland
  • Sponsor Investigative Site
    Poznań, 61-545, Poland
  • Sponsor Investigative Site
    Kyiv, 03151, Ukraine
  • Sponsor Investigative Site
    Poltava, 36011, Ukraine
  • Sponsor Investigative Site
    Ternopil', 46002, Ukraine
  • Sponsor Investigative Site
    Vinnitsa, 21018, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 12, 2021
StartActual
Mar 25, 2021
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Last update
Aug 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04752371
Lead sponsor
Apollo Therapeutics Ltd
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Mar 25, 2021
Primary completion
May 24, 2022
Completion
May 24, 2022
Last update
Aug 23, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camoteskimab

Start the discussion